Advertisement

Loading...

Zai Lab Limited

9688.HKHKSE
Healthcare
Biotechnology
HK$15.90
HK$2.20(16.06%)
Hong Kong Market is Open • 11:48

Zai Lab Limited (9688.HK) Stock Competitors & Peer Comparison

See (9688.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
9688.HKHK$14.75+5.28%15.4B-10.96-HK$1.25N/A
6160.HKHK$183.40+7.19%257.8B115.17HK$1.49N/A
1801.HKHK$89.95+4.47%146.1B160.19HK$0.53N/A
2269.HKHK$34.72+10.71%136.5B25.21HK$1.31N/A
9926.HKHK$137.00+2.93%119.8B-119.45-HK$1.09N/A
1177.HKHK$6.21+6.15%105.3B39.27HK$0.15+1.53%
1530.HKHK$24.16-0.49%53.4B20.77HK$1.09+1.10%
9995.HKHK$106.20+7.44%52.7B65.62HK$1.46N/A
3759.HKHK$20.26+10.89%51.4B19.40HK$0.97+1.16%
2696.HKHK$73.40+5.38%37.9B40.79HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

9688.HK vs 6160.HK Comparison April 2026

9688.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9688.HK stands at 15.4B. In comparison, 6160.HK has a market cap of 257.8B. Regarding current trading prices, 9688.HK is priced at HK$14.75, while 6160.HK trades at HK$183.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9688.HK currently has a P/E ratio of -10.96, whereas 6160.HK's P/E ratio is 115.17. In terms of profitability, 9688.HK's ROE is -0.23%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 9688.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 9688.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions